Kristin Yarema
CEO
Poseida Therapeutics
Poseida Therapeutics utilizes its proprietary non-viral piggyBac® DNA Delivery System and Cas-CLOVER™ Site-Specific Gene Editing System to develop allogeneic CAR-T therapies targeting life-threatening cancers and genetic diseases. The company aims to provide functional cures and improved treatment options for patients suffering from multiple myeloma and rare genetic disorders.
- Biotechnology
Updated 22 months ago
Funding
Raised to date
$50MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current CAR-T cell therapies for cancer and genetic diseases often rely on viral vectors for gene delivery, which can have limitations in terms of payload size, immunogenicity, and manufacturing complexity. Developing effective allogeneic CAR-T therapies also requires precise and efficient gene editing to prevent rejection and ensure therapeutic efficacy.
Solution
Poseida Therapeutics develops allogeneic CAR-T therapies using its proprietary non-viral piggyBac® DNA Delivery System and Cas-CLOVER™ Site-Specific Gene Editing System. The piggyBac system enables the insertion of large genetic payloads into the genome, while Cas-CLOVER facilitates accurate site-specific gene editing in multiple cell types. This approach aims to create off-the-shelf CAR-T therapies that can provide functional cures and improved treatment options for patients with life-threatening cancers and genetic diseases. The company focuses on developing differentiated treatments by targeting specific cell populations and advancing allogeneic CAR-T therapies with an early memory phenotype.
Target Audience
The primary target audience includes patients suffering from life-threatening cancers, such as multiple myeloma, and individuals with rare genetic disorders who can benefit from advanced cell and gene therapies.
Features
- piggyBac® DNA Delivery System: A non-viral gene delivery system capable of inserting large genetic payloads.
- Cas-CLOVER™ Site-Specific Gene Editing System: Enables precise gene editing with site-specific deletions, insertions, and knock-ins.
- Allogeneic CAR-T Therapy Development: Focuses on creating off-the-shelf CAR-T therapies for cancer and genetic diseases.
- Early Memory Phenotype: Advances CAR-T therapies with an early memory phenotype for enhanced persistence and efficacy.